Pasche B - Search Results

1

Tgf-beta signaling alterations and colon cancer.

Bellam N, Pasche B. Bellam N, et al. Among authors: pasche b. Cancer Treat Res. 2010;155:85-103. doi: 10.1007/978-1-4419-6033-7_5. Cancer Treat Res. 2010. PMID: 20517689 Review.

2

Type I transforming growth factor beta receptor maps to 9q22 and exhibits a polymorphism and a rare variant within a polyalanine tract.

Pasche B, Luo Y, Rao PH, Nimer SD, Dmitrovsky E, Caron P, Luzzatto L, Offit K, Cordon-Cardo C, Renault B, Satagopan JM, Murty VV, Massagué J. Pasche B, et al. Cancer Res. 1998 Jul 1;58(13):2727-32. Cancer Res. 1998. PMID: 9661882

3

TbetaR-I(6A) is a candidate tumor susceptibility allele.

Pasche B, Kolachana P, Nafa K, Satagopan J, Chen YG, Lo RS, Brener D, Yang D, Kirstein L, Oddoux C, Ostrer H, Vineis P, Varesco L, Jhanwar S, Luzzatto L, Massagué J, Offit K. Pasche B, et al. Cancer Res. 1999 Nov 15;59(22):5678-82. Cancer Res. 1999. PMID: 10582683

4

Role of transforming growth factor beta in cancer.

Pasche B. Pasche B. J Cell Physiol. 2001 Feb;186(2):153-68. doi: 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J. J Cell Physiol. 2001. PMID: 11169452 Review.

5

TGF-beta signaling alterations in cancer.

Bian Y, Kaklamani V, Reich J, Pasche B. Bian Y, et al. Among authors: pasche b. Cancer Treat Res. 2003;115:73-94. doi: 10.1007/0-306-48158-8_3. Cancer Treat Res. 2003. PMID: 12613193 Review. No abstract available.

6

TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies.

Kaklamani VG, Hou N, Bian Y, Reich J, Offit K, Michel LS, Rubinstein WS, Rademaker A, Pasche B. Kaklamani VG, et al. Among authors: pasche b. J Clin Oncol. 2003 Sep 1;21(17):3236-43. doi: 10.1200/JCO.2003.11.524. J Clin Oncol. 2003. PMID: 12947057

7

Role of TGF-beta in cancer and the potential for therapy and prevention.

Kaklamani VG, Pasche B. Kaklamani VG, et al. Among authors: pasche b. Expert Rev Anticancer Ther. 2004 Aug;4(4):649-61. doi: 10.1586/14737140.4.4.649. Expert Rev Anticancer Ther. 2004. PMID: 15270668 Review.

8

No major association between TGFBR1*6A and prostate cancer.

Kaklamani V, Baddi L, Rosman D, Liu J, Ellis N, Oddoux C, Ostrer H, Chen Y, Ahsan H, Offit K, Pasche B. Kaklamani V, et al. Among authors: pasche b. BMC Genet. 2004 Sep 22;5:28. doi: 10.1186/1471-2156-5-28. BMC Genet. 2004. PMID: 15385056 Free PMC article.

9

Combined genetic assessment of transforming growth factor-beta signaling pathway variants may predict breast cancer risk.

Kaklamani VG, Baddi L, Liu J, Rosman D, Phukan S, Bradley C, Hegarty C, McDaniel B, Rademaker A, Oddoux C, Ostrer H, Michel LS, Huang H, Chen Y, Ahsan H, Offit K, Pasche B. Kaklamani VG, et al. Among authors: pasche b. Cancer Res. 2005 Apr 15;65(8):3454-61. doi: 10.1158/0008-5472.CAN-04-2961. Cancer Res. 2005. PMID: 15833881

10

TGFBR1*6A may contribute to hereditary colorectal cancer.

Bian Y, Caldes T, Wijnen J, Franken P, Vasen H, Kaklamani V, Nafa K, Peterlongo P, Ellis N, Baron JA, Burn J, Moeslein G, Morrison PJ, Chen Y, Ahsan H, Watson P, Lynch HT, de la Chapelle A, Fodde R, Pasche B. Bian Y, et al. Among authors: pasche b. J Clin Oncol. 2005 May 1;23(13):3074-8. doi: 10.1200/JCO.2005.00.281. J Clin Oncol. 2005. PMID: 15860866

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters